Chongqing Lummy Pharmaceutical’s Generic Ramosetron Passes GQCE in China
China-based Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) has announced that its generic version of...
Drug
Sirius Therapeutics Pursues First-in-Human Trial for SRSD107 in Australia
Sino-US biotech Sirius Therapeutics has announced its pursuit of Investigational New Drug (IND) approval in...
ImmVira’s MVR-T3011 IV Achieves Positive Outcomes in US Phase I Clinical Study
Shenzhen-based biotechnology company ImmVira has announced the successful completion of Phase I clinical studies in...
Novartis’ Remibrutinib Meets Milestones in Late-Stage Chronic Spontaneous Urticaria Studies
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that two late-stage studies for its Bruton’s...
Roche’s Lymphoma Therapy Columvi Receives NMPA Approval for Adult Patients with Relapsed DLBCL
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has received market approval from...
Janssen Presents Real-World Data on Tremfya’s Efficacy in Treatment-Resistant Psoriatic Arthritis
Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical unit, Janssen, has presented real-world efficacy data for...
ImmuneOnco Biopharmaceuticals’ Timdarpacept (IMM01) Earns Orphan Drug Designation for CMML
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received orphan drug...
Abbisko Therapeutics’ CD73 Inhibitor ABSK051 Clears for Phase I Clinical Trial in China
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...
US FDA Approves HutchMed and Takeda’s Fruzaqla for Metastatic Colorectal Cancer Treatment
The US Food and Drug Administration (FDA) has granted approval to HutchMed (NASDAQ: HCM) and...
Janssen’s Nipocalimab Shows Promising Results in Phase II Rheumatoid Arthritis Trial
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced the results of...
Abbisko Therapeutics Receives FDA Approval for Phase I Study of FGFR4 Inhibitor ABSK012
Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
Chengdu Kanghong Pharmaceutical’s KH629 Receives FDA Approval for NASH Clinical Trial
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a China-based pharmaceutical company, has announced that...
Gilead Sciences and Arcus Biosciences Announce Positive Phase II Data for Domvanalimab Combination Therapy
Gilead Sciences (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have this week released preliminary data...
Clover Biopharmaceuticals Submits Market Filing for Seasonal Influenza Vaccine in Brazil
China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the submission of a market filing for...
Boehringer Ingelheim’s Aldosterone Synthase Inhibitor BI 690517 Shows Promise in CKD Phase II Trial
Germany-based Boehringer Ingelheim (BI) has published the results of a Phase II trial for its...
RinuaGene Receives US FDA IND Approval for HPV-Associated Tumor mRNA Vaccine RG002
RinuaGene, a leading mRNA specialist headquartered in Suzhou, has announced that it has received Investigational...
Enhertu Receives Priority Review Status for HER2-Positive Gastric Cancer Treatment in China
The Center for Drug Evaluation (CDE) website has indicated that Enhertu (trastuzumab deruxtecan), a HER2-targeted...
MicuRx Pharmaceuticals Secures Clinical Trial Approvals for MRX-4 and Contezolid in Multiple Countries
Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received clinical trial...
Bayer Unveils Real-World Insights on Kerendia for CKD and T2D Management
Germany-headquartered Bayer (ETR: BAYN) recently published interim insights from a significant real-world observational study focusing...
Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...